Pointing to Ozempic as a paradigm shift, an elite rehab center is experimenting with GLP-1s to tame many forms of addiction.

The Global Naltrexone Market is valued at approximately USD 21.0 billion in 2023 and is anticipated to grow with a steady growth rate of more than 3.6% over the forecast period 2024-2032. Request To ...

A research team from Virginia Commonwealth University has found that a drug currently in clinical trials for brain disorders ...

The session emphasized different strategies to initiate buprenorphine, naltrexone, acamprosate, gabapentin, and phenobarbital ...

In a paper released in Addiction, scientists reported that people with a history of alcohol use disorder who were prescribed these medications were 50% less likely to binge drink. The results were ...

About The Study: In this cohort study of opioid-related index health care events, race and ethnicity–based and insurance-based disparities in access to medications for opioid use ...

--Clearmind Medicine Inc.,, a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, recently ...

Naltrexone Pharmacology In 1994, naltrexone, an opioid receptor antagonist, became the second medication after disulfiram to be approved by the FDA as a treatment for alcohol dependence.

Recent comparisons of naltrexone and acamprosate using systematic literature review conclude that, although both drugs are effective as adjuvant therapies for alcohol dependence, acamprosate is ...